Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC

Completed · Phase 2 · Has a placebo group

Conditions studied: Small Cell Lung Cancer

In brief

This was a study to investigate the potential clinical benefit of trilaciclib (G1T28) in preserving the bone marrow and the immune system, and enhancing antitumor efficacy when administered with carboplatin, etoposide, and atezolizumab (E/P/A) therapy in first line treatment for patients with newly diagnosed extensive-stage SCLC. The study was a randomized, double-blinded, placebo-controlled design. Approximately, 100 patients were randomized to trilaciclib + E/P/A or placebo + E/P/A in the study.

Key facts

Study ID

NCT03041311

Run by

G1 Therapeutics, Inc.

People needed

107

Starts

2017-06-29

Expected to finish

2020-10-29

Last updated by the study team

2025-09-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may not qualify if…

• Limited-stage SCLC
• Prior chemotherapy for limited or extensive-stage SCLC
• Prior treatment with immunotherapies including but not limited to cluster of differentiation 137 agonists or immune checkpoint blockade therapies (such as anti-programmed cell death protein 1 (PD-1), anti-programmed death-ligand 1(PD-L1), and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) therapeutic antibodies).
• Presence of symptomatic brain metastases requiring immediate treatment with radiation therapy or steroids.
• Malignancies other than SCLC within 3 years prior to randomization, with the exception of those with negligible risk of metastasis or death treated with expected curative outcome
• History of idiopathic pulmonary fibrosis, organizing pneumonia, drug induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan
• Active, known, suspected autoimmune disease requiring systemic treatment in the past 2 years
• Uncontrolled ischemic heart disease or uncontrolled symptomatic congestive heart failure
• Known history of stroke or cerebrovascular accident within 6 months prior to enrollment
• Serious active infection at the time of enrollment
• Psychiatric illness/social situations that would limit study compliance
• Other uncontrolled serious chronic disease or conditions that in the investigator's opinion could affect compliance or follow-up in the protocol
• Known human immunodeficiency virus, known active hepatitis B, or hepatitis C
• Radiotherapy to any site or radiotherapy within 2 weeks prior to enrollment
• Receipt of any investigational medication within 4 weeks prior to enrollment
• Administration of attenuated vaccine within 4 weeks before enrollment or anticipation that such a live attenuated vaccine will be required during the study
• Influenza vaccination should be given during influenza season only (approx. Oct to March). Patients must not receive live, attenuated influenza vaccine (eg, FluMist) within 4 weeks prior to enrollment at any time during the study, and at least 5 months after the last dose of atezolizumab.
• Patients with a condition requiring systemic treatment with either corticosteroids ( > 10 mg daily prednisone equivalents) or other immunosuppressive medications (including but not limited to cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor agents) within 14 days of study drug administration. Inhaled or topical steroids ad adrenal replacement dosed > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.
• Hypersensitivity to any of the components of the formulation of etoposide or etoposide phosphate
• Hypersensitivity to carboplatin or other platinum-containing compounds or to mannitol
• History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
• Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
• Legal incapacity or limited legal capacity
• Pregnant or lactating women

Where it is running

• Beverly Hills Cancer Center — Beverly Hills, California, United States
• St. Jude Heritage Healthcare — Fullerton, California, United States
• Loma Linda University — Loma Linda, California, United States
• UCLA Medical Center - Santa Monica Hematology And Oncology — Santa Monica, California, United States
• Redwood Regional Medical Group (RRMG) - Fountain Grove — Santa Rosa, California, United States
• Singing River Health System — Whittier, California, United States
• Piedmont Cancer Institute — Atlanta, Georgia, United States
• Northside Hospital - Georgia Cancer Specialists — Atlanta, Georgia, United States
• Joliet Oncology-Hematology Associates — Joliet, Illinois, United States
• Horizon Oncology Center — Lafayette, Indiana, United States
• Ochsner Clinic Foundation — New Orleans, Louisiana, United States
• St. Louis Cancer Care, LLP, North County — Bridgeton, Missouri, United States
• The Alvin J. Siteman Cancer Center - Center for Advanced Med — St Louis, Missouri, United States
• Summit Medical Group, P.A. — Morristown, New Jersey, United States
• Northern Westchester Hospital — Mount Kisco, New York, United States
• Trinity Health - Trinity CancerCare Center — Minot, North Dakota, United States
• Oklahoma University - Peggy and Charles Stephenson Cancer Center — Oklahoma City, Oklahoma, United States
• Gibbs Cancer Center — Spartanburg, South Carolina, United States
• Valley Cancer Associates — Harlingen, Texas, United States
• Millennium Oncology — Houston, Texas, United States
• Virginia Cancer Specialists — Arlington, Virginia, United States
• Blue Ridge Cancer Care — Blacksburg, Virginia, United States
• Fort Belvoir Community Hospital — Fort Belvoir, Virginia, United States
• Complex Oncology Center - Burgas — Burgas, Bulgaria
• Multiprofile Hospital for Active Treatment "Serdika", Sofia — Sofia, Bulgaria

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.